Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

By Alana Hippensteele, MA

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

By Alana Hippensteele, MA

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 10th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 10th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 29th 2017

5 Takeaways for Payers and Providers From the NCCN Meeting on Quality Metrics

Surabhi Dangi-Garimella, PhD

Key lessons learnt at the National Comprehensive Cancer Network's policy meeting: Redefining Quality Measurement in Oncology.

September 29th 2017

Navigating the Quality Landscape in Oncology: Pitfalls and Lessons Learned

Surabhi Dangi-Garimella, PhD

Ensuring access to appropriate data and then using the information to improve healthcare outcomes remains an ongoing challenge-this was the conclusion drawn by panelists participating at the National Comprehensive Cancer Network’s Oncology Policy Summit on Redefining Quality Measurement in Oncology.

This Week in Managed Care: September 29, 2017

September 29th 2017

This Week in Managed Care: September 29, 2017

This week, the top managed care stories included the end of the latest attempt to repeal the Affordable Care Act; a call to better include the patient's voice in cancer quality metrics; and an argument for caution regarding the newly approved CAR T-cell therapy, Kymriah.

September 29th 2017

Report Finds Hospitals Costlier for Cancer Care Than Community Practices

Christina Mattina

Not only do patients with cancer incur higher costs when treated in the hospital outpatient setting compared with community oncology practices, they also have higher rates of emergency department visits, according to a recent study.

September 28th 2017

Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types

Christina Mattina

After examining over 1000 cases of high-grade gliomas in children and young adults, researchers have split these rare brain tumors into at least 10 different subtypes, which could help clinicians choose and deliver more effective treatments.

Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation

September 28th 2017

Dr Amy Abernethy Outlines How Technology Is Improving Clinical Trial Participation

As clinical trials get more complex and fewer patients are available to participate in any particular trial, technology is going to be critical for improving patient access to trials and making the whole process of being on a trial easier for patients and physicians, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.

September 28th 2017

Early Imaging Can Identify Positive Immunotherapy Responders in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

Combining positron emission tomography and computed tomography early in the treatment plan for patients diagnosed with advanced melanoma can help identify the potential benefit of a specific immunotherapy and avoid the risk of non-beneficial intervention.

September 27th 2017

Research Finds Cancer Survivorship Care Lacking in Advanced Primary Care Practices

Christina Mattina

A new case study of 12 advanced primary care practices found that none provided comprehensive cancer survivorship care, which the authors attributed to insufficient information systems and difficulties identifying survivors.

September 27th 2017

Report: Immune Checkpoint Proteins Are the Focus of Cancer Immunotherapy Development

Alison Rodriguez

Advancements in the cancer immunotherapy pipeline are leading to the production of immune checkpoint inhibitors, and a recent report from Global Business Intelligence (GBI) Research titled “Cancer Immunotherapies-First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets” took a look at the pipeline.

Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge

September 26th 2017

Aaron Lyss: Nuances of Oncology Make Creating Value-Based Payment Models a Challenge

While the healthcare industry moves more toward value-based payment models, oncology practices are at a disadvantage because few payers truly understand the nuances of cancer care to design good oncology payment models, explained Aaron Lyss, director of value-based care for Tennessee Oncology.

September 26th 2017

Title X Health Centers Reducing Cervical Cancer Screening in Accordance With Guidelines

Christina Mattina

Among women treated at health centers receiving federal funding under Title X, the proportion receiving cervical cancer screening tests declined significantly from 2005 to 2015, according to new research.

September 26th 2017

Lending the Patient Voice to Oncology Quality Measurement

Surabhi Dangi-Garimella, PhD

At the National Comprehensive Cancer Network's Oncology Policy Summit, a physician administrator from the MD Anderson Cancer Center discussed weaving the patient focus into outcomes measurements.

September 25th 2017

JAMA Commentary Urges Realistic View of New CAR T-Cell Cancer Therapy

Christina Mattina

While the FDA’s approval of the immunotherapy tisagenlecleucel represents a landmark in the oncology field, the treatment is far from being a cure and should be viewed in context of its $475,000 price tag, a group of oncologists wrote in a commentary published in JAMA.

September 25th 2017

New Advance Value Framework Offered as a Decision-Support Tool for Reimbursement

Surabhi Dangi-Garimella, PhD

Researchers at the London School of Economics and Political Science have developed a multiple criteria decision analysis model, The Advance Value Framework, that payers can utilize for evaluating new medicines that come to the market.

Nat Turner on Flatiron Health's Emphasis on Community Oncologists

September 24th 2017

Nat Turner on Flatiron Health's Emphasis on Community Oncologists

Flatiron Health focuses on helping community oncologists because they still care for the majority of patients with cancer and make it possible for patients to get care without traveling long distances, explained Nat Turner, co-founder and CEO of Flatiron Health.

September 23rd 2017

Immune Adverse Events From Nivolumab Predict Better Survival With NSCLC

Christina Mattina

When immune-related adverse events arise from nivolumab, it may indicate that the therapy is having greater efficacy against non—small-cell lung cancer (NSCLC), as a new study demonstrates a link between these events and improved survival outcomes.

September 21st 2017

Link Found Between Childhood-Onset IBD, Higher Cancer Risk

Christina Mattina

Childhood-onset inflammatory bowel disease (IBD) is known to cause painful gastrointestinal symptoms, but a new study of Swedish patients finds that it is also associated with an increased risk of cancer.

September 20th 2017

Review Outlines Recent Advances in Radiotherapy for Cancer

Christina Mattina

A new review article published in the New England Journal of Medicine explores the recent developments in radiotherapy that have improved survival and quality of life for patients with cancer.

September 20th 2017

Physicians Develop Guidelines to Manage CAR T-Cell Toxicity

Surabhi Dangi-Garimella, PhD

Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.

September 19th 2017

Encouraging Physical Activity After Cancer Requires Oncologist Involvement, Researchers Say

Christina Mattina

A new commentary suggests that interventions to promote physical activity in survivors of cancer should be delivered at home and guided by oncologists.

September 19th 2017

Fine-tuning Enzyme Could Help Manage Diabetes, Obesity, Cancer

Experiments with baker's yeast showed why a fat-regulating enzyme is needed in the body.

September 18th 2017

New CDC Report Provides Update on Incidence Rates of Pediatric ALL

Surabhi Dangi-Garimella, PhD

New results published in CDC’s Morbidity and Mortality Weekly Report have identified a surge in pediatric acute lymphoblastic leukemia (ALL) during the period 2001 to 2008, followed by stabilization during 2008 to 2014.

September 18th 2017

Rates of Preventive Mastectomy for Breast Cancer Influenced by Surgeon Attitudes

Christina Mattina

In light of rising rates of preventive mastectomies among women with breast cancer, a new study looks at whether patient and surgeon factors, including attitudes toward breast conservation, affect the odds of receiving this surgery.

Dr Michael Kolodziej on the Challenges of Value-Based Payment Models in Oncology

September 16th 2017

Dr Michael Kolodziej on the Challenges of Value-Based Payment Models in Oncology

There are a number of challenges with implementing value-based payment models in oncology, but it's an exciting time and offshoots of the Oncology Care Model (OCM) can "revolutionize" cancer care delivery, said Michael Kolodziej, MD, national medical director of managed care strategy at Flatiron Health.

September 15th 2017

Real-World Data Used to Inform Approval of Low-Dose Cabazitaxel for Prostate Cancer

Surabhi Dangi-Garimella, PhD

Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.

September 15th 2017

Copanlisib Receives Accelerated Approval for Relapsed Follicular Lymphoma

Christina Mattina

Patients with relapsed follicular lymphoma now have a new treatment option: copanlisib, a kinase inhibitor that was recently approved through the FDA’s accelerated approval process.

September 14th 2017

First Anticancer Biosimilar Treatment Approved for Multiple Indications

Surabhi Dangi-Garimella, PhD

The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.

September 14th 2017

Representatives Probe CMS for Further Detail on New CAR-T Therapy Payment Agreement

Christina Mattina

After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement.

September 13th 2017

FDA Announces Progress, Next Steps in Streamlining Orphan Drug Review Process

Christina Mattina

FDA Commissioner Scott Gottlieb, MD, announced the agency’s progress in streamlining the orphan drug review process and outlined plans to close a loophole currently hindering pediatric drug research.

September 12th 2017

Bringing Drugs to Market Costs Less Than Previously Thought, Study Finds

Christina Mattina

How much does it cost for a drug maker to develop a new drug? Prior estimates have put this figure as high as $2.7 billion, but a new study indicates that the median cost of development for 10 cancer drugs was actually $648 million-a substantial discrepancy.

...

68 69 70 71 72 73 74 75 76

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions